Jaime Rubin - Concepedia

Author

Jaime Rubin

Vertex Pharmaceuticals (United States)ORCID

Also Known As

Hildegarde Paz-Diaz, J Rubin, J. Rubin, J.L. Rubin, Jaime L Rubin, Jaime L. Rubin, Jaime Rubin

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Vertex Pharmaceuticals (United States)Harvard University Pfizer (United States)Rainbow Babies & Children's Hospital Case Western Reserve University

About

Jaime Rubin is an author at Vertex Pharmaceuticals (United States) specializing in medicine, health economics, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	426
2	Public Health	2	2	188
3	Epidemiology	2	2	188
4	Pathology	1	1	280
5	Pulmonary Medicine	1	1	44

Jaime Rubin

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study Michael W. Konstan, Edward F. McKone, Richard B. Moss, The Lancet Respiratory Medicine MedicineF508del-cftr MutationPathologyCombination Lumacaftor	2016	280
Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del Andrea Lopez, Conor Daly, G. Vega-Hernández, Journal of Cystic Fibrosis	2023	126
Economic model of a birth cohort screening program for hepatitis C virus Lisa J. McGarry, Vivek Pawar, H. Panchmatia, Hepatology	2011	112
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States Jaime Rubin, Lisa J. McGarry, David Strutton, Vaccine VaccinationPreventive MedicineHealth EconomicsMedicineEconomic Impact	2010	102
Cost Estimation of Cardiovascular Disease Events in the US Amy K. O’Sullivan, Jaime Rubin, Joshua Nyambose, PharmacoEconomics Cardiovascular DiseaseHealth EconomicsCost EstimationHealth Care CostCost Effectiveness	2011	86
Clinical and Economic Burden of Community‐Acquired Pneumonia in the Medicare Fee‐for‐Service Population Holly Yu, Jaime Rubin, Stephan Dunning, Journal of the American Geriatrics Society	2012	80
The Effect of Hepatitis C Treatment Response on Medical Costs: A Longitudinal Analysis in an Integrated Care Setting M. Michele Manos, Jeanne Darbinian, Jaime Rubin, Journal of Managed Care Pharmacy	2013	50
Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States Jaime Rubin, Sarah Thayer, Angela Watkins, Current Medical Research and Opinion	2017	47
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1 Susanna A. McColley, Michael W. Konstan, Bonnie W. Ramsey, Journal of Cystic Fibrosis Translational MedicineAdvanced Lung DiseasePulmonary ExacerbationsPulmonary PharmacologyPulmonary Medicine	2018	44
Modeling long-term health outcomes of patients with cystic fibrosis homozygous for <i>F508del-CFTR</i> treated with lumacaftor/ivacaftor Jaime Rubin, Lasair O’Callaghan, C. Pelligra, Therapeutic Advances in Respiratory Disease	2019	29

Page 1